

# Torrent Pharma

Estimate change	↔
TP change	↔
Rating change	↔

**CMP: INR3,623**      **TP: INR3,580 (-1%)**      **Neutral**

## Robust Brazil and DF growth drives earnings

### Valuation caps upside

- Torrent Pharma (TRP) delivered in-line revenue/EBITDA for the quarter. However, there was a miss on earnings due to lower other income. Despite geographic headwinds, the company has managed to maintain consistent profitability.
- TRP has shown robust, better-than-industry growth in the Brazilian market in FY25 as well as in 1QFY26, led by new launches and market share gains. However, part of the growth was offset by currency headwinds.
- The strong growth in the consumer health segment, supported by the addition of MRs and a focused approach on chronic therapies, has driven improved performance in the domestic formulation (DF) segment.
- The German business continues to face adverse factors, dragging constant currency growth in this segment.
- New launches are expected to drive the momentum of the US generics segment.
- We largely maintain our earnings estimate for FY26/FY27. We value TRP at 40x 12M forward earnings to arrive at a TP of INR3,580. We expect 10%/14% revenue/EBITDA CAGR over FY25-27, led by superior execution in the DF/Brazil/US market. The JB Chemicals & Pharma acquisition is expected to enhance TRP's chronic portfolio with limited overlap. It will also strengthen TRP's existing MR base, increasing reach and deepening presence.
- Having said that, we believe the current valuation factors in the earnings upside adequately. Hence, we reiterate our Neutral stance on the stock.

Bloomberg	TRP IN
Equity Shares (m)	338
M.Cap.(INRb)/(USDb)	1226.1 / 14.1
52-Week Range (INR)	3635 / 2886
1, 6, 12 Rel. Per (%)	12/3/15
12M Avg Val (INR M)	1409

### Financials & Valuations (INRb)

Y/E March	FY25	FY26E	FY27E
Sales	115.2	129.7	143.5
EBITDA	37.6	43.3	49.2
Adjusted PAT	19.6	23.7	29.4
EBIT Margin (%)	25.7	26.5	28.0
Cons. Adj EPS (INR)	57.8	70.1	86.8
EPS Gr. (%)	22.7	21.0	24.0
BV/Sh. (INR)	448.6	538.1	649.0

### Ratios

Net D-E	0.4	0.3	0.2
RoE (%)	27.1	28.4	29.3
RoCE (%)	20.1	22.7	24.6
Payout (%)	37.0	36.1	36.1

### Valuation

P/E (x)	55.9	51.7	41.7
EV/EBITDA (x)	29.8	28.5	24.5
Div. Yield (%)	0.5	0.6	0.7
FCF Yield (%)	1.6	2.2	3.2
EV/Sales (x)	10.9	9.5	8.4

### Shareholding Pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	68.3	68.3	71.3
DII	8.7	8.4	7.3
FII	16.1	16.3	14.2
Others	6.9	7.0	7.3

FII includes depository receipts

### Sales growth; stable margins; lower tax drives 19% YoY earnings growth

- Sales grew 11.2% YoY to INR31.8b (in-line).
- DF revenue grew 10.8% YoY to INR18.1b (57% of sales). US generics grew 19% YoY to INR3.1b (10% of sales).
- Germany sales grew 8.5% YoY to INR3.1b (10% of sales). In CC terms, sales were stable on a YoY basis.
- Brazil business grew 11.2% YoY to INR2.2b (7% of sales). In CC terms, sales grew 16% YoY for the quarter.
- US generics sales grew 19% YoY (+16% in CC terms) to INR3b (USD36m) in 1QFY26. RoW sales grew 10% YoY at INR5.3b (17% of sales).
- Gross margin was stable YoY at 75.6% for 1QFY26.
- There was a one-time impact of INR150m related to acquisition costs.
- Adj. for the same, EBITDA margin expanded 60bp YoY to 32.9% (our est: 33.3%), driven by an 11% YoY increase in gross profit, partially offset by a rise in employee costs and other expenses of 10%/9% YoY.
- Accordingly, EBITDA grew 13.3% YoY to INR10.5b (vs our est: INR10.7b).
- Adj. PAT grew 18.7% YoY to INR5.6b (our est: INR6b).

**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

### Highlights from the management commentary

- TRP has guided to maintain its FY26 EBITDA margin at the 1QFY26 level.
- The company plans to add 800 MRs in FY26, bringing the total count to ~7,000.
- The acquisition process for JB Chem is largely on track, with CCI approval currently awaited.
- In the Brazilian market, TRP aims to launch 8-10 products annually.
- Approximately 10 launches are also planned for the US market, alongside market share gains in existing products to drive growth.
- Strict prescription guidelines for Ozempic are expected to keep off-label use in check in the Brazilian market. Annual Ozempic sales in Brazil stand at around USD150m and have declined 14-15% over the past year. Wegovy is currently tracking sales of USD150m per quarter. However, a generic version of this product is expected only after a couple of years.

### Quarterly performance (Consolidated)

Quarterly performance (Consolidated)										(INRm)		
Y/E March	FY25				FY26E				FY25	FY26	FY26E	Var.
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1QE	vs Est
Net Revenues	28,590	28,890	28,090	29,590	31,780	32,410	32,498	33,030	1,15,160	1,29,718	32,103	-1.0
YoY Change (%)	10.3	8.6	2.8	7.8	11.2	12.2	15.7	11.6	7.3	12.6	12.3	
EBITDA	9,240	9,390	9,140	9,810	10,470	10,760	10,659	10,768	37,580	42,657	10,690	-2.1
YoY Change (%)	16.8	13.8	5.2	11.1	13.3	14.6	16.6	9.8	11.6	13.5	15.7	
Margins (%)	32.3	32.5	32.5	33.2	32.9	33.2	32.8	32.6	32.6	32.9	33.3	
Depreciation	1,970	1,980	1,990	2,010	2,010	2,223	2,229	2,265	7,950	8,727	2,196	
EBIT	7,270	7,410	7,150	7,800	8,460	8,537	8,430	8,503	29,630	33,931	8,494	-0.4
YoY Change (%)	21.2	18.8	9.0	14.7	16.4	15.2	17.9	9.0	15.7	14.5	16.8	
Margins (%)	25.4	25.6	25.5	26.4	26.6	26.3	25.9	25.7	25.7	26.2	26.5	
Interest	750	640	570	560	560	540	520	510	2,520	2,130	580	
Other Income	240	-160	330	-180	-370	175	182	171	230	158	172	
PBT before EO Expense	6,760	6,610	6,910	7,060	7,530	8,172	8,092	8,164	27,340	31,959	8,086	-6.9
One-off expenses	200	0	0	410	150	0	0	0	610	150	0	
PBT after EO Expense	6,560	6,610	6,910	6,650	7,380	8,172	8,092	8,164	26,730	31,809	8,086	
Tax	1,990	2,080	1,880	1,670	1,900	2,141	2,080	2,131	7,620	8,252	2,062	
Rate (%)	29.4	31.5	27.2	23.7	25.2	26.2	25.7	26.1	27.9	25.8	25.5	
Reported PAT	4,570	4,530	5,030	4,980	5,480	6,031	6,013	6,033	19,110	23,557	6,024	-9.0
Adj PAT	4,709	4,530	5,030	5,287	5,591	6,031	6,013	6,033	19,556	23,668	6,024	-7.2
YoY Change (%)	24.6	17.4	31.9	17.8	18.7	33.1	19.5	14.1	22.7	21.0	27.9	
Margins (%)	16.5	15.7	17.9	17.9	17.6	18.6	18.5	18.3	17.0	18.2	18.8	

**Key performance indicators (Consolidated)**

Y/E March	FY25				FY26E				FY25	FY26	FY26E	Var.
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1QE	vs Est
India formulations	16,350	16,320	15,810	15,450	18,110	18,311	17,944	17,690	63,930	72,056	18,230	0.66
YoY Change (%)	14.7	13.0	11.7	12.0	10.8	12.2	13.5	14.5	12.8	12.7	11.5	
US generics	2,590	2,680	2,710	3,020	3,080	3,071	3,320	3,569	11,000	13,040	2,739	-11.07
YoY Change (%)	-11.6	8.1	-1.1	15.3	18.9	14.6	22.5	18.2	2.0	18.5	5.8	
Latin America	1,960	2,630	2,910	3,510	2,180	3,156	3,434	3,686	11,000	12,455	3,136	43.85
YoY Change (%)	3.2	4.4	-6.7	-5.6	11.2	20.0	18.0	5.0	-2.3	13.2	60.0	
Europe	2,840	2,880	2,820	2,860	3,080	2,966	2,961	3,003	11,390	12,010	2,954	-4.10
YoY Change (%)	10.1	8.3	4.4	2.1	8.5	3.0	5.0	5.0	6.1	5.4	4.0	
Others (ROW+CDMO)	4,850	4,380	3,840	4,750	5,330	4,906	4,838	5,083	17,840	20,157	5,044.0	-5.37
YoY Change (%)	14.4	-2.7	-16.7	5.3	9.9	12.0	26.0	7.0	0.0	13.0	4.0	
<b>Cost Break-up</b>												
RM Cost (% of Sales)	24.3	23.5	24.0	24.1	24.4	24.1	24.2	23.9	24.4	24.1	23.7	
Staff Cost (% of Sales)	19.2	18.8	19.5	19.0	19.0	18.2	18.8	19.0	19.5	18.8	18.4	
Other Cost (% of Sales)	24.2	25.2	24.0	23.8	23.7	24.5	24.2	24.5	24.7	24.2	25.1	
Gross Margins(%)	75.7	76.5	76.0	75.9	75.6	75.9	75.8	76.1	75.6	75.9	76.3	
EBITDA Margins(%)	32.3	32.5	32.5	33.2	32.9	33.2	32.8	32.6	32.6	32.9	32.8	
EBIT Margins(%)	25.4	25.6	25.5	26.4	26.6	26.3	25.9	25.7	25.7	26.2	25.8	



## Torrent Pharma

**Exhibit 1: Top 10 drugs**

Secondary sales grew 12.3% YoY in Jun'25 vs. 6.5% in May'25. Nexpro-Rd / Nikoran / Nexpro outperformed in Jun'25.

Drug	Therapy	MAT Jun'25			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'25
<b>Total</b>		<b>81,746</b>	<b>8.8</b>	<b>100.0</b>	<b>9.7</b>	<b>12.3</b>
Shelcal	Vitamins/Minerals/Nutrients	3,346	-4.0	33.6	-1.9	1.9
Chymoral	Pain / Analgesics	3,242	4.1	88.8	0.9	3.6
Nexpro-Rd	Gastro Intestinal	2,523	18.9	25.3	20.8	20.6
Shelcal Xt	Vitamins/Minerals/Nutrients	2,364	5.4	21.0	4.6	3.9
Nikoran	Cardiac	2,252	12.0	52.8	17.2	23.5
Unienzyme	Gastro Intestinal	1,659	2.1	41.3	4.0	5.9
Nebicard	Cardiac	1,440	3.5	53.2	8.1	10.6
Losar	Cardiac	1,394	6.8	61.6	2.8	5.6
Nexpro	Gastro Intestinal	1,332	24.0	29.4	27.6	30.5
Veloz-D	Gastro Intestinal	1,287	4.7	10.2	5.0	9.2

\* Three months: Apr-Jun'25

Source: IQVIA, MOFSL


**Exhibit 2: Therapy mix (%)**

Except for VMN/Pain, all other therapies witnessed positive double-digit growth in Jun'25.


	Share	MAT growth (%)	3M*	Jun'25
<b>Total</b>	<b>100.0</b>	<b>8.8</b>	<b>9.7</b>	<b>12.3</b>
Cardiac	27.5	12.0	11.6	13.9
Gastro Intestinal	17.9	11.0	12.2	14.1
Neuro / Cns	14.9	10.6	12.9	15.0
Vitamins/Minerals/Nutrients	9.6	2.7	4.5	7.8
Anti-Diabetic	9.4	16.3	13.9	14.1
Pain / Analgesics	7.9	3.3	2.9	6.3

Source: IQVIA, MOFSL

**Exhibit 3: Acute vs. Chronic (MAT growth)**



**Exhibit 4: Growth distribution (%) (MAT Jun'25)**






## Key takeaways from the management interaction

- TRP expects constant currency growth in Brazil to be 10-12% in FY26 vs the industry YoY growth of 9%. The company targets 8-10 launches annually over the next 4-5 years.
- TRP's chronic therapies grew at 13% YoY vs 9% at the industry level in the DF segment.
- Consumer health formed 10-15% of DF sales for the quarter. TRP had 4-5 meaningful launches, with 9-10 line extensions over the past year.
- TRP has about 14 brands with annual sales of INR1b+ each.
- Disruption related to a third-party supplier has impacted the German market's performance.
- While the US business has shown decent YoY growth, it remains an unprofitable business.
- ETR is expected to be 25-26% for FY26.


## Key exhibits

**Exhibit 5: US sales rose 16.1% YoY in 1QFY26 (CC terms)**




Source: MOFSL, Company

**Exhibit 6: India sales grew ~10.8% YoY in 1QFY26**




Source: MOFSL, Company

**Exhibit 7: Germany sales' YoY growth revives following the sequential downtrend**




Source: Company, MOFSL

**Exhibit 8: Brazil's revenue growth in INR terms reverses the negative trend**




Source: Company, MOFSL

**Exhibit 9: EBITDA margin contracted marginally 20bp YoY in 1QFY26**



Source: MOFSL, Company

**Exhibit 10: Adjusted PAT up ~18.7% YoY in 1QFY26**



Source: MOFSL, Company

## DF and Brazil outperform, while US revives; valuation limits upside potential

### DF – Multi-prong strategy in place to outpace industry

- TRP grew 11% YoY to INR18.1b in the Indian business vs industry growth of 8%. According to IMS, this growth was primarily driven by a 6% YoY growth in pricing, supported by a 3.5% YoY growth in volume and a 2.5% YoY growth contribution from new launches—reflecting a well-balanced mix of growth levers.
- Notably, in its major therapies of CNS, gastro-intestinal, and anti-diabetic, TRP posted 15%/14%/14% YoY growth in Q1FY26, according to IMS.
- The company is targeting field force expansion from 3,600 MRs in 2022 to 6,400 MRs in FY2025, with a YoY improvement in productivity and market share. It aims to further increase its MR strength to ~7000 by the end of FY26.
- In the consumer health segment, brands such as Shelcal and Tedibar witnessed robust traction, driving overall growth for the quarter.
- To accelerate growth, the company has leveraged synergies between the prescription and consumer segments, driving increased brand performance.
- Overall, the consumer health segment has progressed well, aided by channel activations, increased distribution in newer towns, and growth in the e-commerce business.
- Accordingly, we expect a 13.8% sales CAGR in DF to INR84b over FY25-27.

### Brazil – Strong product pipeline and long gestation period for approval augurs well for sustained growth

- In Q1FY26, the Brazilian business grew 11.2% YoY to INR2.2b. The performance was aided by the performance of top brands and new launches.
- During FY25, Brazil operations posted 9% growth on a constant currency basis. Compared to this, constant currency revenue for 1QFY26 rose 16% to BRL143m.
- TRP currently has 62 products under ANVISA review, with management aiming to launch 2-3 products per division annually—providing a steady pipeline to support growth in the Brazilian business.
- Accordingly, we expect a 14% sales CAGR over FY25-27, reaching INR14.2b.


### US – Growth on a revival path

- After two years of dismal performance in US generics, there have been green shoots visible in this segment over the past two quarters.
- Compared to just 2% YoY growth in FY25, TRP exhibited 19% YoY growth in US generics sales to INR3b. In cc terms, it exhibited 16% YoY growth for the quarter.
- TRP has a healthy pipeline of new launches in addition to the higher off-take of existing products for FY26.
- TRP continues to implement R&D efforts to enhance the ANDA pipeline in the US generics segment.
- We expect an 18% sales CAGR over FY25-27, reaching INR15b.

### Reiterate Neutral


- We largely maintain our earnings estimate for FY26/FY27. We value TRP at 40x 12M forward earnings to arrive at a TP of INR3,580. We expect 10%/14% revenue/EBITDA CAGR over FY25-27, led by a superior execution in the DF/Brazil/US market. The JB Chemicals & Pharma acquisition is expected to enhance TRP's chronic portfolio with limited overlap. It will also strengthen TRP's existing pool of MRs, increasing reach and deepening presence.
- Having said this, we believe the current valuation factors in the earnings upside adequately. Hence, we reiterate our Neutral stance on the stock.

**Exhibit 11: P/E chart**



Source: MOFSL, Company, Bloomberg


**Exhibit 12: EV/EBITDA chart**



Source: MOFSL, Company, Bloomberg


## Story in charts

**Exhibit 13: Expect total sales CAGR of 11.6% over FY25-27**




Source: Company, MOFSL

**Exhibit 14: EBITDA margin to expand 167bp over FY25-27**




Source: Company, MOFSL

**Exhibit 15: Expect 13.8% DF sales CAGR over FY25-27**




Source: Company, MOFSL

**Exhibit 16: US revenue expected to maintain positive growth momentum**




Source: Company, MOFSL

**Exhibit 17: Expect ~13.8% sales CAGR in Brazil over FY25-27**



Source: Company, MOFSL

**Exhibit 18: Expect 13.4% sales CAGR in Germany over FY25-27**



Source: Company, MOFSL



## Financials and valuations

### Income Statement

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Net Sales</b>	<b>79,390</b>	<b>80,050</b>	<b>85,080</b>	<b>95,820</b>	<b>1,07,280</b>	<b>1,15,160</b>	<b>1,29,718</b>	<b>1,43,479</b>
Change (%)	4.3	0.8	6.3	12.6	12.0	7.3	12.6	10.6
<b>EBITDA</b>	<b>21,700</b>	<b>25,010</b>	<b>24,310</b>	<b>28,288</b>	<b>33,680</b>	<b>37,580</b>	<b>43,326</b>	<b>49,213</b>
Margin (%)	27.3	31.2	28.6	29.5	31.4	32.6	33.4	34.3
Depreciation	2,346	2,374	6,620	7,070	8,080	7,950	8,896	8,995
<b>EBIT</b>	<b>19,354</b>	<b>22,636</b>	<b>17,690</b>	<b>21,218</b>	<b>25,600</b>	<b>29,630</b>	<b>34,430</b>	<b>40,218</b>
Int. and Finance Charges	4,510	3,580	2,550	3,330	3,540	2,520	2,198	1,003
Other Income - Rec.	1,220	570	1,970	850	580	230	700	1,050
<b>PBT before EO Expense</b>	<b>16,064</b>	<b>19,626</b>	<b>17,110</b>	<b>18,738</b>	<b>22,640</b>	<b>27,340</b>	<b>32,932</b>	<b>40,265</b>
EO Expense/(Income)	0	160	4,850	267	-880	610	0	0
<b>PBT after EO Expense</b>	<b>16,064</b>	<b>19,466</b>	<b>12,260</b>	<b>18,471</b>	<b>23,520</b>	<b>26,730</b>	<b>32,932</b>	<b>40,265</b>
Current Tax	1,620	2,740	4,490	6,110	6,959	7,618	9,219	10,870
Deferred Tax	0	0	0	0	1	2	2	2
Tax	1,620	2,740	4,490	6,110	6,960	7,620	9,221	10,872
Tax Rate (%)	10.1	14.0	26.2	32.6	30.7	27.9	28.0	27.0
<b>Reported PAT</b>	<b>14,444</b>	<b>16,726</b>	<b>7,770</b>	<b>12,361</b>	<b>16,560</b>	<b>19,110</b>	<b>23,711</b>	<b>29,394</b>
<b>Adj PAT</b>	<b>9,496</b>	<b>12,680</b>	<b>11,617</b>	<b>12,581</b>	<b>15,942</b>	<b>19,556</b>	<b>23,711</b>	<b>29,394</b>

### Balance Sheet

(INR m)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	850	850	850	1,692	1,692	1,692	1,692	1,692
Total Reserves	47,390	57,530	58,680	60,288	66,868	74,218	89,364	1,08,141
<b>Net Worth</b>	<b>48,240</b>	<b>58,380</b>	<b>59,530</b>	<b>61,980</b>	<b>68,560</b>	<b>75,910</b>	<b>91,056</b>	<b>1,09,834</b>
Deferred liabilities	-4330	-4210	-4940	-5440	-5550	2340	2340	2340
Total Loans	44,080	36,450	40,180	52,970	39,380	30,260	25,380	18,380
<b>Capital Employed</b>	<b>87,990</b>	<b>90,620</b>	<b>94,770</b>	<b>1,09,510</b>	<b>1,02,390</b>	<b>1,08,510</b>	<b>1,18,776</b>	<b>1,30,554</b>
Gross Block	1,02,918	1,02,848	1,04,548	1,27,128	1,38,405	1,43,978	1,47,478	1,50,481
Less: Accum. Deprn.	24,098	30,678	37,298	44,368	52,448	60,398	69,294	78,289
<b>Net Fixed Assets</b>	<b>78,820</b>	<b>72,170</b>	<b>67,250</b>	<b>82,760</b>	<b>85,957</b>	<b>83,580</b>	<b>78,184</b>	<b>72,191</b>
Capital WIP	7,120	8,710	6,720	8,330	2,810	3,670	3,670	3,670
Investments	40	440	440	450	350	470	470	470
<b>Curr. Assets</b>	<b>50,070</b>	<b>55,220</b>	<b>51,650</b>	<b>53,140</b>	<b>56,110</b>	<b>56,230</b>	<b>74,123</b>	<b>1,05,326</b>
Inventory	21,480	26,810	24,620	22,300	22,790	25,410	28,237	31,493
Account Receivables	16,490	15,230	16,330	19,440	18,440	18,670	22,052	28,696
Cash and Bank Balance	6,660	6,040	4,030	5,710	8,390	5,790	16,800	37,358
Loans & Advances	5,440	7,140	6,670	5,690	6,490	6,360	7,034	7,779
<b>Curr. Liability &amp; Prov.</b>	<b>48,060</b>	<b>45,920</b>	<b>31,290</b>	<b>35,170</b>	<b>42,837</b>	<b>35,440</b>	<b>37,670</b>	<b>51,103</b>
Account Payables	40,490	37,910	23,490	27,300	34,387	26,350	28,186	39,403
Provisions	7,570	8,010	7,800	7,870	8,450	9,090	9,484	11,701
<b>Net Current Assets</b>	<b>2,010</b>	<b>9,300</b>	<b>20,360</b>	<b>17,970</b>	<b>13,273</b>	<b>20,790</b>	<b>36,453</b>	<b>54,223</b>
<b>Appl. of Funds</b>	<b>87,990</b>	<b>90,620</b>	<b>94,770</b>	<b>1,09,510</b>	<b>1,02,390</b>	<b>1,08,510</b>	<b>1,18,776</b>	<b>1,30,554</b>

## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>EPS</b>	<b>21.4</b>	<b>28.1</b>	<b>37.5</b>	<b>34.3</b>	<b>37.2</b>	<b>47.1</b>	<b>57.8</b>	<b>70.1</b>	<b>86.8</b>
Cash EPS	31.1	49.6	56.4	42.5	57.4	72.8	159.9	192.7	226.9
BV/Share	139.6	142.5	172.5	175.9	183.1	202.6	448.6	538.1	649.0
DPS	9.0	16.0	11.2	10.3	11.2	14.1	17.3	21.0	26.1
Payout (%)	43.0	45.1	27.4	54.0	36.8	34.8	37.0	36.1	36.1
<b>Valuation (x)</b>									
P/E	169.7	129.2	96.8	105.6	97.5	77.0	62.7	51.7	41.7
Cash P/E	116.4	73.1	64.2	85.3	63.1	49.8	22.7	18.8	16.0
P/BV	26.0	25.4	21.0	20.6	19.8	17.9	8.1	6.7	5.6
EV/Sales	16.7	15.9	15.7	14.8	13.3	11.7	10.9	9.5	8.4
EV/EBITDA	65.0	58.3	50.3	52.0	45.0	37.3	33.3	28.5	24.5
<b>Return Ratios (%)</b>									
RoE	15.5	19.9	23.8	19.7	20.7	24.4	27.1	28.4	29.3
RoCE	16.4	19.7	21.3	14.9	13.9	16.3	20.1	22.7	24.6
RoIC	18.9	22.7	26.0	16.4	16.0	19.1	22.6	25.2	31.4
<b>Working Capital Ratios</b>									
Asset Turnover (x)	0.8	0.9	0.9	0.9	0.9	1.0	1.1	1.1	1.1
Fixed Asset Turnover (x)	0.9	1.0	1.1	1.2	1.3	1.3	1.4	1.6	1.9
Debtor (Days)	65	71	72	68	68	64	59	57	65
Inventory (Days)	93	99	122	106	85	78	81	79	80
Working Capital Turnover (Days)	-15	-21	15	70	47	17	48	55	43
<b>Leverage Ratio (x)</b>									
Interest Cover Ratio	3.5	4.3	6.3	6.9	6.4	7.2	11.8	15.7	40.1
Debt/Equity	1.0	0.9	0.6	0.7	0.9	0.6	0.4	0.3	0.2

### Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Oper. Profit/(Loss) before Tax	5,617	11,866	15,263	12,259	18,472	23,521	26,730	32,932	40,265
Depreciation/Amorisation	6,177	6,544	6,578	6,622	7,066	8,083	7,950	8,896	8,995
Interest/Dividends Recd.	4,873	4,428	3,479	2,479	3,187	3,421	2,320	1,498	-47
Direct Taxes Paid	-2,812	-2,840	-1,755	-4,210	-3,981	-4,981	-6,030	-9,219	-10,870
(Inc)/Dec in WC	994	-3,858	-3,383	-3,519	-182	4,181	-2,710	-4,373	1,317
<b>CF from Operations</b>	<b>14,849</b>	<b>16,138</b>	<b>20,182</b>	<b>13,631</b>	<b>24,561</b>	<b>34,224</b>	<b>28,260</b>	<b>29,734</b>	<b>39,661</b>
Others Items	3,132	-2,209	-128	4,399	-880	-1,564	-2,410	394	2,217
<b>CF from Operating incl EO Expense</b>	<b>17,981</b>	<b>13,929</b>	<b>20,054</b>	<b>18,030</b>	<b>23,681</b>	<b>32,661</b>	<b>25,850</b>	<b>30,128</b>	<b>41,878</b>
(inc)/dec in FA	-6,605	-4,028	-3,340	-1,958	-4,152	-2,991	-5,930	-3,500	-3,003
<b>Free Cash Flow</b>	<b>11,376</b>	<b>9,901</b>	<b>16,713</b>	<b>16,072</b>	<b>19,529</b>	<b>29,670</b>	<b>19,920</b>	<b>26,628</b>	<b>38,875</b>
(Pur)/Sale of Investments	589	3,805	-1,635	-348	474	331	350	0	0
Others Items	3,561	2,515	537	345	-19,675	1,062	180	-674	-745
<b>CF from Investments</b>	<b>-2,456</b>	<b>2,292</b>	<b>-4,438</b>	<b>-1,961</b>	<b>-23,354</b>	<b>-1,598</b>	<b>-5,400</b>	<b>-4,174</b>	<b>-3,748</b>
Issue of shares	0	0	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-5,013	-3,452	-9,563	-8,464	12,434	-13,933	-9,530	-4,880	-7,000
Interest Paid	-5,034	-4,854	-3,561	-2,577	-3,030	-3,710	-2,620	-1,498	47
Dividend Paid	-3,097	-7,185	-3,385	-6,769	-8,630	-10,153	-10,830	-8,562	-10,613
<b>CF from Fin. Activity</b>	<b>-13,145</b>	<b>-15,490</b>	<b>-16,508</b>	<b>-17,811</b>	<b>774</b>	<b>-27,796</b>	<b>-22,980</b>	<b>-14,944</b>	<b>-17,571</b>
<b>Inc/Dec of Cash</b>	<b>2,380</b>	<b>731</b>	<b>-893</b>	<b>-1,742</b>	<b>1,101</b>	<b>3,266</b>	<b>-2,530</b>	<b>11,010</b>	<b>20,558</b>
Opening Balance	7,020	5,888	6,618	5,726	3,984	5,085	8,351	5,730	16,740
Add/(less) Forex in Cash/Cash eq							-91	0	0
<b>Closing Cash and Cash Eq.</b>	<b>9,401</b>	<b>6,618</b>	<b>5,726</b>	<b>3,984</b>	<b>5,085</b>	<b>8,351</b>	<b>5,730</b>	<b>16,740</b>	<b>37,298</b>
Bank balances*	-1,240	40	310	50	630	40	60	60	60
<b>Total Cash and Cash Eq.</b>	<b>8,161</b>	<b>6,658</b>	<b>6,036</b>	<b>4,034</b>	<b>5,715</b>	<b>8,391</b>	<b>5,790</b>	<b>16,800</b>	<b>37,358</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.

7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of

Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.